2008年4月
Which skeletal myoblasts and how to be transplanted for cardiac repair?
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 369
- 号
- 1
- 開始ページ
- 270
- 終了ページ
- 276
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/j.bbrc.2007.11.084
- 出版者・発行元
- ACADEMIC PRESS INC ELSEVIER SCIENCE
Clinical efficacy of skeletal myoblast (skMb) transplantation is controversial whether this treatment produces beneficial outcome in patients with dilated cardiomyopathy (DCM). Based on immunological tolerance between wild-type and DCM hamsters with the deletion of delta-sarcoglycan (SG) gene, skMb engraftment in TO-2 myocardium (3 x 10(5) cells in similar to 100 mg heart) was verified by the donor-specific expression of delta-SG transgene constitutively produced throughout myogenesis. At 5 weeks after the transplantation, the cell rates expressing fast-myosin heavy chain (MHC) exceeded slow-MHC in delta-SG(+) cells. Fifteen weeks after (corresponding to similar to 12 years in humans), fast MHC+ cells nullified, but the delta-SG(+) and slow MHC+ cell number remained unaltered. These skMbs fused with host cardiomyocytes via connexin-43 and intercalated disc, modestly improving the hemodynamics without arrhythmia, when engrafted skMbs were sparsely disseminated in autopsied myocardium. These results provide us evidence that disseminating delivery of slow-MHC+ myoblasts is promising for repairing DCM heart using histocompatible skeletal myoblasts in future. (c) 2007 Elsevier Inc. All rights reserved.
- リンク情報
-
- DOI
- https://doi.org/10.1016/j.bbrc.2007.11.084
- CiNii Articles
- http://ci.nii.ac.jp/naid/80019412405
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/18047831
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000254478000035&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.1016/j.bbrc.2007.11.084
- ISSN : 0006-291X
- CiNii Articles ID : 80019412405
- PubMed ID : 18047831
- Web of Science ID : WOS:000254478000035